WinstonWınston
Back
Stock

DENTSPLY SIRONA

XRAY
27
Medical - Instruments & Supplies · Healthcare
Also trades as: 0I8F.L GBP 0.09 (-0.34%)
Price
$9.43
-0.07 (-0.74%)
Market Cap
$1.88B
Exchange
NASDAQ
Winston Score
27
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Oct 24, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
13/30
Growth
Weak
3/20
Cash Flow
Weak
1/10
Stability
Good
5/10
Valuation
Data not available
0/10
Ownership
Weak
2/15
Dividends
Good
3/5

27 of 100 counted points = Winston Score 27.

Track this stock — start free trial

Share count falling — buybacks

−9.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 220.2M (2021) → 199.4M (2025)

§Winston Score History

The full picture

Dentsply Sirona makes tools and supplies that dentists use every day. Its products include dental implants, braces, crowns, X-ray machines, and the materials dentists use to fill cavities or clean teeth. The company sells to dental offices, clinics, and dental schools around the world, making it one of the largest dental products companies globally.

The company earns money by selling both equipment (like imaging machines and dental chairs) and consumable supplies that dentists reorder regularly, such as materials and small instruments. Dentsply Sirona operates in over 40 countries, with significant revenue coming from North America and Europe. Its broad product portfolio and long-standing relationships with dental professionals give it some competitive staying power, but the company has faced pressure from slowing dental procedure volumes, internal restructuring challenges, and rising competition from lower-cost rivals. A key risk going forward is whether management can successfully execute its ongoing turnaround plan and restore consistent profit growth.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-4.1% YoY

YoY Growth Rate

Revenue declining

Reported EPS Growth

+178.3% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.23

30 Jun 2026: $0.18

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$150M/ year

↓ Declining (-9% vs prior year)

4.1% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$244M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

DENTSPLY SIRONA's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
54.9%
Healthy — 54.9% gross margin
Profit after running costs
Operating Margin
9.1%
Modest — 9.1% operating margin
Return on the money invested
ROCE
11.6%
Below par — 11.6% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-0.8%
Shrinking sales (-0.8% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
3.9%
Thin free cash flow (3.9%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.71
Elevated debt (1.71)
Covers its interest
Interest Cover
4.68x
Adequate interest coverage (4.7x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
7.55%
Healthy income — 7.55% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
+0.0%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial